Report Phase 3 ATHENA trial data for Rubraca
Delivered after the deadline (90 days after the deadline)
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 11 Jan 2021
- Due
- 31 Dec 2021
- Delivered
- 31 Mar 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Data from Phase 3 ATHENA trial of Rubraca® (rucaparib) as 1LM OC monotherapy anticipated 2H21”
What we found
Evidence strength A What the grades mean
The company announced the Phase 3 ATHENA-MONO trial data on March 31, 2022, which was after the original 2H21 deadline due to a slower than expected event count.
-
A Clovis Oncology, Inc. 8-K filed 2022-02-23
“Top-line data from the ATHENA Phase 3 study in first-line maintenance treatment ovarian cancer setting evaluating Rubraca monotherapy versus placebo (ATHENA-MONO) are expected in the second quarter of 2022 based on a slower than expected event count.” ✓ confirmed on the page
-
A Clovis Oncology, Inc. 10-Q filed 2022-05-05
“On March 31, 2022, we announced positive top-line data from the monotherapy portion of the ATHENA (GOG 3020/ENGOT-ov45) trial (ATHENA-MONO)” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Deliverable
- Phase 3 ATHENA trial data
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Clovis Oncology, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C466301-021623 · Corrections policy